Drug intelligence / Profile preview

XeroDuo (XeroThera)

Development stage: Preclinical
Lead developer: XeroThera
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

XeroDuo is a preclinical-stage medical device developed by XeroThera, Inc. It is a xerogel-based dual antibiotic delivery system designed for local application at surgical sites during surgery. Utilizing a proprietary nanoporous, oxide-based xerogel biomaterial (composed of silica, calcium, and phosphate), XeroDuo provides controlled, simultaneous release of two antibiotics to target resistant bacterial infections, such as MRSA. It is intended for the prevention and treatment of surgical site infections (SSI) and implant-associated infections. The platform allows surgeons to select specific antibiotics at the time of surgery based on clinical needs.

Brand names: XeroDuo
Other names: XeroDuo-XeroThera

Beyond the preview

Go deeper on XeroDuo (XeroThera).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XeroDuo (XeroThera).

Explore the full profile